key: cord-0902035-t6a6uxlh
authors: Mehrabi Nasab, Entezar; Athari, Seyyed Shamsadin
title: The first report of 2:1 atrioventricular block following COVID‐19 vaccination
date: 2022-05-04
journal: Clin Case Rep
DOI: 10.1002/ccr3.5797
sha: cddacbd58af27f97c9092618f819e8b160708906
doc_id: 902035
cord_uid: t6a6uxlh

A 65‐year‐old man became ill a few days after being vaccinated against the COVID‐19 by the Sinopharm vaccine. Laboratory investigations, trans‐thoracic echocardiography, and chest computed tomography scanning (CT‐scan) retrieved normal results. The patient's electrocardiogram showed sinus rhythms with 2:1 AV‐block and a narrow QRS complex. Coronary angiography showed mild coronary artery disease.

The coronavirus infection disease 2019 (COVID-19), the recent pandemic ravaging the world, is a serious health threat to mankind. Current research on COVID-19 vaccines shows that most of their known side effects are mild and self-limiting and do not require any specific treatment. 1, 2 However, some rare and partially recognized side effects of these vaccines may create serious lifethreatening conditions. There are various types of atrioventricular (AV) conduction disorders. Second-degree type 2 AV block (mobiz II), including 2:1 AV block, results from the sudden failure of AV conduction without a progressive increase in the AV conduction time. 3 In this case report, we presented a patient who developed 2:1 AV block a few days after being vaccinated for COVID-19.

A 65-year-old man, without a noticeable health condition or history of serious diseases, was referred to the emergency department of our hospital (Shohada Hospital). His main complaints were dizziness and mild dyspnea. The patient's symptoms started a few days after receiving a COVID-19 vaccine (Sinopharm).

The patient's vital signs were as follows: blood pressure = 100/60 mmHg, respiratory rate = 15 breaths per minute, pulse rate = 37 beats per minute (bpm), oxygen saturation (room air) = 98%, and body temperature = 37°C. During lung clinical examination, auscultation was clear, and cardiovascular examination revealed no murmur. Laboratory investigations retrieved normal results ( Table 1 ). The initial 12-lead electrocardiography (12-lead ECG) showed sinus rhythms with 2:1 second-degree AV block (2:1 AV block), a narrow QRS complex, a ventricular rate of 37 bpm, and an atrial rate of 74 bpm ( Figure 1 ).

Chest CT-scan showed no abnormality ( Figure 2 ). Trans-thoracic echocardiography showed normal left ventricular size and left ventricular systolic and diastolic functions (LVEF = 55%). Also, the size and systolic function of the right ventricle were normal. There were no signs of valvular diseases, and pulmonary artery pressure (PAP) was normal (PAP = 15-20) (Figure 3 ).

The patient underwent coronary angiography, which showed mild coronary artery disease without significant arterial stenosis ( Figure 4) . A temporary pacemaker (TPM) was inserted, and the patient was closely observed for several days afterwards, showing no AV block improvement. Therefore, a permanent pacemaker (PPM) was finally installed. After 1 week of admission to the hospital, the patient was discharged with a good general condition, and he was recommended to visit for the follow-up.

According to ethical guidelines, informed consent (in Persian, his national language) was obtained from the patient. Also, the patient was followed up for 1 month after admission, and he was recommended to visit every 6 months to check the performance of the PPM.

Vaccination is regarded as the best preventive intervention against the COVID-19 infection and is believed to save millions of lives each year. 2 Several brands of COVID-19 vaccines have been developed, including Sinopharm 4 that works based on the virus inactivating technology and promotes immunity by introducing inactivated SARS-CoV-2 viruses into the body. 2 The most commonly reported side effects of this vaccine include headache, myalgia, and fever, which are generally mild and self-limiting with no requirement for treatment. 5 Limited studies have reported an association between the COVID-19 infection and AV block. [6] [7] [8] However, there are no reports suggesting an association between AV block and COVID-19 vaccines. In this study, we presented the case of a 65-year-old man who developed 2:1-AV block a few days after receiving a COVID-19 vaccine. The patient did not present extensive systemic, myocardial, or coronary involvement. There is little information on the cardiac complications of COVID-19 vaccines. Whether AV block development in our patient was secondary to an exaggerated inflammatory response or not remains unknown. Currently, there are limited guidelines on how to treat these patients. The American College of Cardiology (ACC) and American Heart Association (AHA) recommend cardiac pacemaker insertion for patients with second-degree AV block only if they present with symptomatic bradycardia, regardless of the site or type of the block. 9 Considering the unpredictable course of second-degree AV block, a In future studies, two issues should be addressed. First, the cardiac complications of COVID-19 vaccines should be more thoroughly evaluated to divulge the pathophysiology of the conduction disorders caused by these vaccines. Second, a suitable therapeutic method should be designed for the patients developing AV block after COVID-19 vaccination.

Not applicable.

There is no conflict of interest.

EMN and SSA participated equally in case analysis and drafting the manuscript.

Written informed consent was obtained from the patient to publish this report in accordance with the journal's patient consent policy.

Seyyed Shamsadin Athari https://orcid. org/0000-0002-6355-6378

Major cardiac concerns in therapy and vaccinations for COVID-19

Side effects and perceptions following Sinopharm COVID-19 vaccination

Functional 2:1 A-V block within the His-Purkinje system, simulation of type II second-degree A-V block

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

A review of the progress and challenges of developing a vaccine for COVID-19

Transient complete heart block in a patient with critical COVID-19

Heart brake: an unusual cardiac manifestation of COVID-19

Heart block in patients with coronavirus disease 2019: a case series of 3 patients infected with SARS-CoV-2

Atypical presentation of COVID-19 as subclinical myocarditis with persistent highdegree atrioventricular block treated with pacemaker implant

The first report of 2:1 atrioventricular block following COVID-19 vaccination